The relevant disclosure is attached

Fortis Healthcare Limited Tower-A, Unitech Business Park, Block-F, South City 1, Sector – 41, Gurgaon, Haryana – 122 001 (India) Tel 0124 492 1033 Fax 0124 492 1041 Emergency 105010 Email: secretarial@fortishealthcare.com Website : www.fortishealthcare.com November 5, 2026 FHL/SEC/2026-27 The National Stock Exchange of India Ltd. BSE Limited Scrip Symbol: FORTIS Scrip Code: 532843 Sub: Press Release under Regulation 30 SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 Dear Madam/Sir, Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, please find enclosed herewith the ‘Press Release’ on Financial results for the quarter and half year ended September 30, 2026. The date and time of occurrence of event is Thursday, November 5, 2026 at 06:05 PM (IST). This is for your information and records. Thanking you, Yours Sincerely, For Fortis Healthcare Limited Satyendra Chauhan Company Secretary & Compliance Officer M. No. - A14783 Encl: As stated above FORTIS HEALTHCARE LIMITED Regd. Office : Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062 Tel :0172-4692222, Fax : 0172-5096221, CIN : L85110PB1996PLC045933 Press Release November 05, 2026 Fortis Healthcare announces Q2 FY27 Financial Results ➢ Consolidated Revenues for Q2 FY27 at INR 2,735 Cr, up 17.3%; PAT Margin at 11.7% (vs Q2 FY26 at 14.1%) ➢ Hospital Business Revenues for Q2 FY27 at INR 2,340 Cr, up 18.6%; PAT Margin at 12.1% (vs Q2 FY26 at 14.5%) ➢ Diagnostics Business Gross Revenues for Q2 FY27 at INR 448 Cr, up 12.2%; PAT Margin at 15.2% (vs Q2 FY26 at 14.8%) Gurugram, November 05, 2026: Fortis Healthcare Ltd. (“Fortis” or the “Company”), amongst India’s leading healthcare delivery companies, today announced its unaudited consolidated financial results for the quarter and half year ended September 30, 2026. Financial Highlights % Change % Change Consolidated (INR Cr) Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Y-o-Y Y-o-Y Revenue 2,331 2,735 17.3% 4,498 5,280 17.4% Profit Before Tax 402 429 6.8% 740 783 5.8% (Before exceptional items) Exceptional Item* 24 3 36 13 Profit After Tax*^ 329 320 -2.5% 596 593 -0.4% Profit After Tax Margin 14.1% 11.7% 13.2% 11.2% Profit After Tax after Minority Interest and Share in 322 312 -3.0% 582 579 -0.6% Associates* Earnings per share (EPS) 4.26 4.14 7.71 7.67 * Exceptional gain pertains primarily to reversal of impairment in an associate Company; PAT and PATMI includes exceptional gain. ^ Consolidated PAT is after accounting for adjustments related to intercompany eliminations % Change % Change Hospital Business (INR Cr) Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Y-o-Y Y-o-Y Revenue 1,974 2,340 18.6% 3,812 4,527 18.8% Profit After Tax* 287 284 -1.1% 512 502 -1.8% Profit After Tax Margin 14.5% 12.1% 13.4% 11.1% * PAT for Q2 FY27 and H1 FY27 includes exceptional gain of INR 3 Cr and INR 13 Cr respectively (corresponding previous period includes exceptional gain of INR 24 Cr and INR 36 Cr respectively) which pertains primarily to reversal of impairment in an associate Company Diagnostics Business % Change % Change Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 (INR Cr) Y-o-Y Y-o-Y Revenue^ 400 448 12.2% 768 855 11.2% Profit After Tax 59 68 15.8% 101 123 21.1% Profit After Tax Margin 14.8% 15.2% 13.2% 14.4% ^ Diagnostics business revenue is on Gross Basis; Consolidated financials include diagnostics business revenue net of intercompany elimination; Net Revenues stood at INR 394 Cr in Q2 FY27 versus INR 357 Cr in Q2 FY26 and INR 752 Cr in H1 FY27 versus INR 686 Cr in H1 FY26. Press Release November 05, 2026 Balance Sheet • The Company’s net debt as of 30th September 2026 stood at INR 2,188 Cr with a Net Debt to EBITDA of 0.87x as compared to 0.96x as on 30th September 2025 (basis Q2 annualized EBITDA). Net debt to equity was at 0.20x versus 0.23x as on 30th September 2025. HOSPITAL BUSINESS HIGHLIGHTS KPIs Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Occupancy 71% 72% 70% 70% ARPP* (INR Lakhs) 1.96 2.10 1.98 2.10 ALOS (Days) 4.18 4.20 4.14 4.20 * Average Revenue per IP Patient is basis Gross IP revenue, excluding daycare procedures such as Chemotherapy, Radiotherapy, Dialysis, etc. • Revenue growth in the hospital business for the quarter was led by a ~7% increase in ARPP and an increase of ~9% in occupied beds compared to Q2 FY26. • The Company through its wholly owned subsidiary Fortis Hospotel Limited (FHTL), entered into definitive agreements with Seth Sunder Lal Jain Charitable Eye Hospital to provide healthcare services to a 400+ bedded super-specialty hospital in Ashok Vihar, New Delhi. The ~3.1 acre facility is expected to commence operations in 3–4 years, subject to necessary approvals, with operationalization of beds in phases. • The Company through its wholly owned subsidiary International Hospitals Limited (IHL) recently acquired Suguna Hospital, a 110 bedded facility in Rajajinagar, Bengaluru. The transaction includes the acquisition of the hospital’s business operations, building and land. The facility has potential to expand to ~150 beds. • As part of its inorganic growth strategy, the Company aims to further strengthen its presence across key clusters by evaluating strategic M&A and greenfield opportunities including built-to-suit (Sale or Lease) models in established markets such as Mumbai, Kolkata and Hyderabad. These growth initiatives are expected to drive network synergies and strengthen its competitive positioning in these select micro-markets. Additionally, the Company is evaluating similar such growth and expansion opportunities in select attractive and underserved Tier 2 markets across central India and in proximity to its key clusters in order to further broaden its geographical footprint. DIAGNOSTICS BUSINESS HIGHLIGHTS • Revenue mix of the business continued to improve, with the B2C share increasing to 54% in the current quarter from 52% in Q2FY26. • Continuing with its network expansion strategy, primarily the addition of new customer touch points (CTPs); total CTPs of Agilus as on 30th September 2026 stood at 4,551. • In Q2 FY27, Agilus conducted ~11.39 Mn tests versus ~10.62 Mn tests in Q2 FY26. • The preventive and specialized portfolio revenues in Agilus’ overall revenues grew 28% and 14% respectively in Q2 FY27. Press Release November 05, 2026 Commenting on the results for the quarter, Dr Ashutosh Raghuvanshi, MD and CEO, Fortis Healthcare stated, “We have witnessed another quarter of sustained growth, maintaining our growth trajectory in Q2 FY27 across our hospital and diagnostics businesses. We remain committed to strengthening our clinical capabilities and expanding our presence in key markets. We advanced our network expansion strategy recently through the acquisition of 110 bedded Suguna Hospital in Bengaluru taking the total number of operational beds in the region to approx. 1,000 beds. We also entered into a long-term healthcare services agreement for a 400+ bedded super-specialty hospital in Ashok Vihar, New Delhi. Both these growth initiatives will further strengthen our presence in the Bengaluru and Delhi NCR clusters respectively and support our long-term growth ambitions.” He further added, “Our diagnostics business continued to demonstrate consistent growth and strong operational momentum. With our ongoing capacity expansion initiatives, focus on clinical excellence and disciplined execution of our growth strategy, we remain well positioned to capitalise on the growing demand for quality healthcare services in India and deliver sustainable growth over the coming years.” About Fortis Healthcare Limited: Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates 37 healthcare facilities (including JVs and O&M facilities) across 12 states. The Company’s network comprises over 6,300 operational bed [Showing first 8,000 characters — download PDF for full document]